MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. METHODS: We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. RESULTS: The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (P<0.001 by the log-rank test; hazard ratio, 0.45; 95 percent confidence interval, 0.32 to 0.61). Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. CONCLUSIONS: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Intriguingly, PT2385 treatment of the same PDX cell line in vitro showed no impact on cell viability or proliferation, suggesting that the survival advantage mediated by PT2385 may be linked to inhibition of tumor aspects required for in vivo progression.”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [55]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Indeed, selective HIF-2α inhibition using PT2385 increased animal survival in an orthotropic GBM PDX model although no significant differences in tumor size (detected by bioluminescent imaging) was observed [55].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [55]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (2000) · PubMed · Cited by 891
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationFriedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Ochs, K., & Kaina, B. (2000) · PubMed · Cited by 291
Research works printed but not linked: 8
- Ochs K, 2000, Cancer Res, 60, 5815
- Liu L, 1996, Cancer Res, 56, 5375
- Belanich M, 1996, Cancer Res, 56, 783
- Silber JR, 1999, Clin Cancer Res, 5, 807
- Qian XC, 1997, Cancer Res, 57, 3672
- Esteller M, 1999, Cancer Res, 59, 793
- Palmisano WA, 2000, Cancer Res, 60, 5954
- Quinn JA, 2003, Prog Proc Am Soc Clin Oncol, 22, 103
Cited by
Items 101–200 of 330
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615
Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0805 · Cited by 614
Self-citationChip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
Shao, H., Chung, J., Lee, K., Balaj, L., Min, C., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Lee, H., & Weissleder, R. (2015) · Nature Communications · doi:10.1038/ncomms7999 · Cited by 612
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationThe DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Goldstein, M., & Kastan, M. B. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-081313-121208 · Cited by 590
“The main products of methylating agents such as temozolomide (TMZ) and procarbazine are N7- and N3-methylguanine (N7MeG, N3MeG) and N3-methyladenine (N3MeA).”
BackgroundInfluentialThe role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
Urdinguio, R. G., Sanchez-Mut, J. V., & Esteller, M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70262-5 · Cited by 582
MGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Self-citationCurrent and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.-D., Krex, D., Grauer, O., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31791-4 · Cited by 568
Self-citationEmerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
Gorlia, T., van den Bent, M. J., Hegi, M. E., Mirimanoff, R. O., Weller, M., Cairncross, J. G., Eisenhauer, E., Belanger, K., Brandes, A. A., Allgeier, A., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70384-4 · Cited by 557
Self-citationPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Wojdacz, T. K., & Dobrovic, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm013 · Cited by 551
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 541
Self-citationCentral Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Lim, M., Weller, M., Idbaih, A., Steinbach, J., Finocchiaro, G., Raval, R. R., Ansstas, G., Baehring, J., Taylor, J. W., Honnorat, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac116 · Cited by 533
Self-citationChemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8554 · Cited by 529
Self-citationWesteneng, H.-J., Debray, T. P. A., Visser, A. E., van Eijk, R. P. A., Rooney, J. P. K., Calvo, A., Martin, S., McDermott, C. J., Thompson, A. G., Pinto, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30089-9 · Cited by 524
Omuro, A., Brandes, A. A., Carpentier, A. F., Idbaih, A., Reardon, D. A., Cloughesy, T., Sumrall, A., Baehring, J., van den Bent, M., Bähr, O., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac099 · Cited by 516
Self-citationEmerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Self-citationThe Need for Multi-Omics Biomarker Signatures in Precision Medicine
Olivier, M., Asmis, R., Hawkins, G. A., Howard, T. D., & Cox, L. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194781 · Cited by 499
Clinical epigenetics: seizing opportunities for translation
Berdasco, M., & Esteller, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0074-2 · Cited by 498
Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2007) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 495
Self-citationEpigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis
Moran, S., Martínez-Cardús, A., Sayols, S., Musulén, E., Balañá, C., Estival-Gonzalez, A., Moutinho, C., Heyn, H., Diaz-Lagares, A., de Moura, M. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30297-2 · Cited by 484
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 473
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 472
Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas
Chang, P., Grinband, J., Weinberg, B. D., Bardis, M., Khy, M., Cadena, G., Su, M.-Y., Cha, S., Filippi, C. G., Bota, D., et al. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5667 · Cited by 472
DNA Methylation Cancer Biomarkers: Translation to the Clinic
Locke, W. J., Guanzon, D., Ma, C., Liew, Y. J., Duesing, K. R., Fung, K. Y. C., & Ross, J. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01150 · Cited by 472
Current concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Self-citationLai, A., Tran, A., Nghiemphu, P. L., Pope, W. B., Solis, O. E., Selch, M., Filka, E., Yong, W. H., Mischel, P. S., Liau, L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2729 · Cited by 458
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 456
Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U., Clement, P. M. J., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 454
Self-citationCahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 452
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 452
Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5370 · Cited by 451
DNA methylation: An epigenetic mark of cellular memory
Kim, M., & Costello, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.10 · Cited by 450
Pyrko, P., Schönthal, A. H., Hofman, F. M., Chen, T. C., & Lee, A. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0625 · Cited by 450
Survival and low-grade glioma: the emergence of genetic information
Claus, E. B., Walsh, K. M., Wiencke, J. K., Molinaro, A. M., Wiemels, J. L., Schildkraut, J. M., Bondy, M. L., Berger, M., Jenkins, R., & Wrensch, M. (2015) · Neurosurgical Focus · doi:10.3171/2014.10.focus12367 · Cited by 445
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., Greenman, C., Edkins, S., Bignell, G., Davies, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0127 · Cited by 434
Rivera, A. L., Pelloski, C. E., Gilbert, M. R., Colman, H., De La Cruz, C., Sulman, E. P., Bekele, B. N., & Aldape, K. D. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop020 · Cited by 434
Lai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 433
Clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Primary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Self-citationLudwig, K., & Kornblum, H. I. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2379-y · Cited by 418
Zalutsky, M. R., Reardon, D. A., Akabani, G., Coleman, R. E., Friedman, A. H., Friedman, H. S., McLendon, R. E., Wong, T. Z., & Bigner, D. D. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.046938 · Cited by 410
Ogino, S., Kawasaki, T., Brahmandam, M., Cantor, M., Kirkner, G. J., Spiegelman, D., Makrigiorgos, G. M., Weisenberger, D. J., Laird, P. W., Loda, M., et al. (2006) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050135 · Cited by 409
An overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma
Qazi, M. A., Vora, P., Venugopal, C., Sidhu, S. S., Moffat, J., Swanton, C., & Singh, S. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx169 · Cited by 408
Taby, R., & Issa, J.-P. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 407
Cairncross, J. G., Wang, M., Jenkins, R. B., Shaw, E. G., Giannini, C., Brachman, D. G., Buckner, J. C., Fink, K. L., Souhami, L., Laperriere, N. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3726 · Cited by 402
Self-citationKmiecik, J., Poli, A., Brons, N. H. C., Waha, A., Eide, G. E., Enger, P. Ø., Zimmer, J., & Chekenya, M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.08.013 · Cited by 389
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 400
Cohen, K. J., Pollack, I. F., Zhou, T., Buxton, A., Holmes, E. J., Burger, P. C., Brat, D. J., Rosenblum, M. K., Hamilton, R. L., Lavey, R. S., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq191 · Cited by 399
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clement, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 394
Self-citationLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 390
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., & Longacre, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021087 · Cited by 386
A multigene predictor of outcome in glioblastoma
Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., Popoff, S., Nutt, C. L., Louis, D. N., Cairncross, J. G., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop007 · Cited by 386
Self-citationPhase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Self-citationKarschnia, P., Young, J. S., Dono, A., Häni, L., Sciortino, T., Bruno, F., Juenger, S. T., Teske, N., Morshed, R. A., Haddad, A. F., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac193 · Cited by 384
Self-citationDNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“Clinical study indicated that patients with glioblastoma containing a methylated MGMT promoter obtained more benefits from TMZ than those who did not have a methylated MGMT promoter (Hegi et al., 2005).”
BackgroundThe ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance
Siebzehnrubl, F. A., Silver, D. J., Tugertimur, B., Deleyrolle, L. P., Siebzehnrubl, D., Sarkisian, M. R., Devers, K. G., Yachnis, A. T., Kupper, M. D., Neal, D., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302827 · Cited by 381
Kulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S., Ryan, D. P., Enzinger, P. C., Meyerhardt, J. A., Clark, J. W., Stuart, K., Fuchs, C. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1476 · Cited by 381
Brandes, A. A., Tosoni, A., Franceschi, E., Sotti, G., Frezza, G., Amistà, P., Morandi, L., Spagnolli, F., & Ermani, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4969 · Cited by 381
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma
Bhat, K. P. L., Salazar, K. L., Balasubramaniyan, V., Wani, K., Heathcock, L., Hollingsworth, F., James, J. D., Gumin, J., Diefes, K. L., Kim, S. H., et al. (2011) · Genes & Development · doi:10.1101/gad.176800.111 · Cited by 377
Deep learning with convolutional neural network in radiology
Yasaka, K., Akai, H., Kunimatsu, A., Kiryu, S., & Abe, O. (2018) · Japanese Journal of Radiology · doi:10.1007/s11604-018-0726-3 · Cited by 368
Bar, E. E., Lin, A., Mahairaki, V., Matsui, W., & Eberhart, C. G. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091021 · Cited by 373
Epigenetic regulation of gene expression in physiological and pathological brain processes
Gräff, J., Kim, D., Dobbin, M. M., & Tsai, L.-H. (2011) · Physiological Reviews · doi:10.1152/physrev.00012.2010 · Cited by 373
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373
Self-citationChanging Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Self-citationDNA methylation profiles in cancer diagnosis and therapeutics
Pan, Y., Liu, G., Zhou, F., Su, B., & Li, Y. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0467-0 · Cited by 373
Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment
Hoelzinger, D. B., Demuth, T., & Berens, M. E. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm187 · Cited by 372
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Emerging treatment strategies for glioblastoma multiforme
Carlsson, S. K., Brothers, S. P., & Wahlestedt, C. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201302627 · Cited by 365
Pediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 360
The time toxicity of cancer treatment
Gupta, A., Eisenhauer, E. A., & Booth, C. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02810 · Cited by 356
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
Pallini, R., Ricci-Vitiani, L., Banna, G. L., Signore, M., Lombardi, D., Todaro, M., Stassi, G., Martini, M., Maira, G., Larocca, L. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0644 · Cited by 355
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Stupp, R., Tonn, J.-C., Brada, M., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq187 · Cited by 348
Self-citationMolecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
Self-citationLok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
MGMT Status as a Clinical Biomarker in Glioblastoma
Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.010 · Cited by 342
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperriere, N. J., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noy132 · Cited by 340
Self-citationPangenomic Classification of Pituitary Neuroendocrine Tumors
Neou, M., Villa, C., Armignacco, R., Jouinot, A., Raffin-Sanson, M.-L., Septier, A., Letourneur, F., Diry, S., Diedisheim, M., Izac, B., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.11.002 · Cited by 340
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
Personalized medicine in oncology: the future is now
Schilsky, R. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3181 · Cited by 337
van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clement, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 330
Self-citation
Metadata
- Authors
- Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E. C., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., & Stupp, R.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- European Organisation for Research and Treatment of Cancer (NL)
- University of Tübingen (DE)
- Erasmus MC (NL)
- Medical University of Vienna (AT)
- Princess Margaret Cancer Centre (CA)
- University Hospital of Bern (CH)
- University Medical Center Utrecht (NL)
- University of Regensburg (DE)
- University of Calgary (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-10
- Volume
- 352
- Issue
- 10
- Pages
- 997-1003
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2105100844
- Cited by
- 7,405
- References
- 22
- Citations by year
- 2026: 344 · 2025: 342 · 2024: 383 · 2023: 407 · 2022: 444 · 2021: 525 · 2020: 442 · 2019: 391 · 2018: 361 · 2017: 390 · 2016: 391 · 2015: 391 · 2014: 360 · 2013: 369 · 2012: 372
- FWCI
- 84.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- glioblastoma, MGMT promoter methylation, O6-methylguanine-DNA methyltransferase, temozolomide, epigenetic silencing, DNA repair, alkylating agents, radiotherapy, survival benefit, prognostic factors
- MeSH terms
- Temozolomide, Brain Neoplasms, Dacarbazine, Glioblastoma, Humans, Promoter Regions, Genetic, Survival Analysis, Randomized Controlled Trials as Topic, Polymerase Chain Reaction, Chemotherapy, Adjuvant, Disease-Free Survival, Antineoplastic Agents, Alkylating, DNA Methylation, O(6)-Methylguanine-DNA Methyltransferase, Gene Silencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.